Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Alpine Immune Sciences, Inc. < Previous 1 2 Next > Alpine Immune Sciences Reports First Quarter 2024 Financial Results May 09, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy April 10, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Vertex Enters Into Agreement to Acquire Alpine Immune Sciences April 10, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN VRTX Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024 April 01, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024 March 21, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference March 20, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results March 18, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results March 07, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences February 26, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences February 01, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie December 21, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 18, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference November 20, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 November 15, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Reports Third Quarter 2023 Financial Results November 14, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 November 13, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Pricing of $150 Million Public Offering November 06, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Proposed Public Offering November 06, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting November 03, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023 November 02, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 October 30, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023 October 13, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c) October 04, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting September 12, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences September 05, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3) August 30, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c) August 22, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Reports Second Quarter 2023 Financial Results August 14, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses May 19, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Reports First Quarter 2023 Financial Results May 11, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.